The Drug-Induced Respiratory Disease Website and App

X. Systemic/Distant conditions, syndromes and reactions

X.i Hypersensitivity reaction (may manifest with fever and/or skin, throat or airway involvement)

X. Systemic/Distant conditions, syndromes and reactions

X.ap Cytokine release syndrome - Cytokine storm

I. Interstitial/parenchymal lung disease

I.e Organizing pneumonia pattern (an area or areas of consolidation on imaging)

II. Pulmonary edema - Acute lung injury - ARDS

II.a Pulmonary edema, noncardiogenic (NCPE)

II. Pulmonary edema - Acute lung injury - ARDS

II.e ARDS - Acute lung injury

IV. Airway involvement

IV.a Bronchospasm - Wheezing - Asthma

V. Central-large-upper airway (incl. pharyngeal-nasal) involvement

V.c Upper airway obstruction other than angioedema or hematoma

VII. Pulmonary vasculopathy

VII.e Fat/oil embolism - The FES embolism syndrome

X. Systemic/Distant conditions, syndromes and reactions

X.f Anaphylaxis-Anaphylactoid reaction (can be fatal)

X. Systemic/Distant conditions, syndromes and reactions

X.i Hypersensitivity reaction (may manifest with fever and/or skin, throat or airway involvement)

X. Systemic/Distant conditions, syndromes and reactions

X.t Fluid retention

XI. Miscellaneous

XI.b Chest pain (acute or subacute), lone or prominent

XII. Cardiovascular involvement / toxicity

XII.u Cardiac- cardiorespiratory/pulmonary arrest

XIX. Pathology

XIX.be Path: Lipid/fat embolism (see also VIe)

I. Interstitial/parenchymal lung disease

I.a Pneumonitis (ILD)

I. Interstitial/parenchymal lung disease

I.n ILD with a granulomatous component

X. Systemic/Distant conditions, syndromes and reactions

X.d Lupus - Lupus syndrome (see also Vd)

X. Systemic/Distant conditions, syndromes and reactions

X.i Hypersensitivity reaction (may manifest with fever and/or skin, throat or airway involvement)

X. Systemic/Distant conditions, syndromes and reactions

X.m Sarcoid-like granulomatosis (endo-/extrathoracic)

XIX. Pathology

XIX.f Path: ILD with a granulomatous component (see also Im)

I. Interstitial/parenchymal lung disease

I.a Pneumonitis (ILD)

I. Interstitial/parenchymal lung disease

I.b Pneumonitis (ILD), acute and/or severe (may cause ARDS)

I. Interstitial/parenchymal lung disease

I.c Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)

I. Interstitial/parenchymal lung disease

I.e Organizing pneumonia pattern (an area or areas of consolidation on imaging)

I. Interstitial/parenchymal lung disease

I.g Pulmonary fibrosis

I. Interstitial/parenchymal lung disease

I.m Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf)

I. Interstitial/parenchymal lung disease

I.n ILD with a granulomatous component

I. Interstitial/parenchymal lung disease

I.r Pulmonary nodulosis

I. Interstitial/parenchymal lung disease

I.ai Acute restrictive lung dysfunction

II. Pulmonary edema - Acute lung injury - ARDS

II.e ARDS - Acute lung injury

III. Pulmonary/alveolar./airway hemorrhage/bleeding

III.a Alveolar hemorrhage (AH), diffuse AH (DAH)

V. Central-large-upper airway (incl. pharyngeal-nasal) involvement

V.a Angioedema (may cause UAO, asphyxia and death)

X. Systemic/Distant conditions, syndromes and reactions

X.i Hypersensitivity reaction (may manifest with fever and/or skin, throat or airway involvement)

X. Systemic/Distant conditions, syndromes and reactions

X.q Neutrophilic dermatosis (Pyoderma, Sweet syndrome)

XII. Cardiovascular involvement / toxicity

XII.i Eosinophilic myocarditis

XVIII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XVIII.a BAL: An excess proportion of lymphocytes

XIX. Pathology

XIX.a Path: NSIP-cellular pattern (see also Ia, Ib)

XIX. Pathology

XIX.f Path: ILD with a granulomatous component (see also Im)

XIX. Pathology

XIX.o Path: Diffuse alveolar damage (DAD-pattern) (see also IL)

XIX. Pathology

XIX.w Path: Pulmonary fibrosis (UIP-pattern)

XIX. Pathology

XIX.ck Path: Lymphoproliferative disease, endothoracic

XX. Infections & related conditions

XX.e Pneumocystis jiroveci pneumonia

XX. Infections & related conditions

XX.h Nontuberculous pulmonary mycobacterial infection/superinfection

XXI. Neoplastic conditions

XXI.b Lymphoproliferative disease (pulmonary, endobronchial, endothoracic)

II. Pulmonary edema - Acute lung injury - ARDS

II.a Pulmonary edema, noncardiogenic (NCPE)

II. Pulmonary edema - Acute lung injury - ARDS

II.e ARDS - Acute lung injury

X. Systemic/Distant conditions, syndromes and reactions

X.f Anaphylaxis-Anaphylactoid reaction (can be fatal)

X. Systemic/Distant conditions, syndromes and reactions

X.i Hypersensitivity reaction (may manifest with fever and/or skin, throat or airway involvement)

X. Systemic/Distant conditions, syndromes and reactions

X.w Multiple organ dysfunction/failure (MODS/MOF)

XII. Cardiovascular involvement / toxicity

XII.u Cardiac- cardiorespiratory/pulmonary arrest

XX. Infections & related conditions

XX.a Respiratory tract infection incl. pneumonia

X. Systemic/Distant conditions, syndromes and reactions

X.i Hypersensitivity reaction (may manifest with fever and/or skin, throat or airway involvement)

X. Systemic/Distant conditions, syndromes and reactions

X.i Hypersensitivity reaction (may manifest with fever and/or skin, throat or airway involvement)

X. Systemic/Distant conditions, syndromes and reactions

X.ap Cytokine release syndrome - Cytokine storm

I. Interstitial/parenchymal lung disease

I.a Pneumonitis (ILD)

I. Interstitial/parenchymal lung disease

I.b Pneumonitis (ILD), acute and/or severe (may cause ARDS)

I. Interstitial/parenchymal lung disease

I.c Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)

I. Interstitial/parenchymal lung disease

I.d Acute eosinophilic pneumonia (AEP)

II. Pulmonary edema - Acute lung injury - ARDS

II.e ARDS - Acute lung injury

IV. Airway involvement

IV.a Bronchospasm - Wheezing - Asthma

X. Systemic/Distant conditions, syndromes and reactions

X.i Hypersensitivity reaction (may manifest with fever and/or skin, throat or airway involvement)

XI. Miscellaneous

XI.b Chest pain (acute or subacute), lone or prominent

XIX. Pathology

XIX.b Path: Eosinophilic pneumonia (subacute or acute) (see also Ic)

XX. Infections & related conditions

XX.e Pneumocystis jiroveci pneumonia

XXIII. Rechallenge data

XXIII.c Tolerance can be induced successfully starting with minute dosage of the drug